311 related articles for article (PubMed ID: 19217030)
1. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
5. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
Ueda J; Iwata T; Ono M; Takahashi M
Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
[TBL] [Abstract][Full Text] [Related]
7. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
[TBL] [Abstract][Full Text] [Related]
8. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
9. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
10. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
11. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
12. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
13. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
14. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases.
Loy TS; Diaz-Arias AA; Bickel JT
Mod Pathol; 1990 May; 3(3):294-7. PubMed ID: 2194212
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
17. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
Kundu UR; Krishnamurthy S
Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
19. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
Marsan C; Gaulier A; Sabatier P; Garcia R
Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]